source
- AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchaseAbbVie said the FDA has approved an antibody-drug conjugate it obtained as part of its $10.1 billion buyout of ImmunoGen for an ultra-rare but aggressive form of blood cancer. On Wednesday, the ...Endpoints · 2mo ago↗ source
- GSK spells out positive Phase 3 data for hepatitis B drug it licensed from IonisGSK has shared detailed results from a pair of late-stage trials testing a chronic hepatitis B treatment originally developed by Ionis Pharmaceuticals, with regulatory reviews underway in four mark…Endpoints · 2mo ago↗ source
- AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as WavePlus news about Kailera, Alfasigma, Junshi and Kura. ⏰ FDA delays AstraZeneca’s camizestrant PDUFA date: The FDA has extended its PDUFA date for AstraZeneca’s breast cancer drug camizestrant, a few…